Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Althea obtains FDA license to manufacture, package product for US market
The FDA’s decision follows a Pre-Approval Inspection (PAI) which was done in April 2011 by the US regulators. The company expects to do the filling and packaging of
The FDA’s decision follows a Pre-Approval Inspection (PAI) which was done in April 2011 by the US regulators. The company expects to do the filling and packaging of
Teva intends to team up with another two Israeli clinical centers for conducting the study (immunotherapy Multikine anti tumor treatments (IT-MATTERS)), which is already ongoing at several clinical
Watson has acquired the progesterone gel from Columbia in July last year. The product helps to reduce the risk of preterm birth in women with short cervical length.
The research which was conducted by Jun Yan of University of Louisville School of Medicine in Louisville, Kentucky supports another study that found that differences in yeast-derived beta-glucan
MPV offers a suite of patient and payer management solutions that help physician practices and hospitals improve collections, minimize denied claims and accelerate reimbursement. MPV through a combination
Edge BioSystems will initially focus on sample preparation for exome, whole genome and RNA sequencing applications. Caliper has developed a suite of next generation sequencing tools, including the
Replagal is an enzyme replacement therapy for the treatment of Fabry disease. With this approval, the company now has two approved facilities, Alewife, and the new Lexington facility,
The company has already received orphan drug designation from the European Medicines Agency for Graspa as a treatment for pancreatic cancer. Erytech Pharma co-founder, vice president and chief
Prior to that Hinchen was the president and chief operating officer of JHP since the formation of the company in 2007. Hinchen said JHP has a wonderful opportunity
Adcetris MAA was filed as a treatment for relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) by Takeda Global Research